SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin
- PMID: 33662449
- PMCID: PMC7919585
- DOI: 10.1016/j.pharmthera.2021.107825
SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin
Abstract
Coronaviruses (CoVs) are a group of single stranded RNA viruses, of which some of them such as SARS-CoV, MERS-CoV, and SARS-CoV-2 are associated with deadly worldwide human diseases. Coronavirus disease-2019 (COVID-19), a condition caused by SARS-CoV-2, results in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with high mortality in the elderly and in people with underlying comorbidities. Results from several studies suggest that CoVs localize in mitochondria and interact with mitochondrial protein translocation machinery to target their encoded products to mitochondria. Coronaviruses encode a number of proteins; this process is essential for viral replication through inhibiting degradation of viral proteins and host misfolded proteins including those in mitochondria. These viruses seem to maintain their replication by altering mitochondrial dynamics and targeting mitochondrial-associated antiviral signaling (MAVS), allowing them to evade host innate immunity. Coronaviruses infections such as COVID-19 are more severe in aging patients. Since endogenous melatonin levels are often dramatically reduced in the aged and because it is a potent anti-inflammatory agent, melatonin has been proposed to be useful in CoVs infections by altering proteasomal and mitochondrial activities. Melatonin inhibits mitochondrial fission due to its antioxidant and inhibitory effects on cytosolic calcium overload. The collective data suggests that melatonin may mediate mitochondrial adaptations through regulating both mitochondrial dynamics and biogenesis. We propose that melatonin may inhibit SARS-CoV-2-induced cell damage by regulating mitochondrial physiology.
Keywords: Apoptosis; Autophagy; COVID-19; Chaperone proteins; Coronaviruses; Fission; Fusion; Melatonin; Mitochondrial dynamics.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest statement The authors declare that there are no conflicts of interest.
Figures
Similar articles
-
SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome.J Immunol. 2014 Sep 15;193(6):3080-9. doi: 10.4049/jimmunol.1303196. Epub 2014 Aug 18. J Immunol. 2014. PMID: 25135833 Free PMC article.
-
In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.Virol J. 2020 Sep 9;17(1):136. doi: 10.1186/s12985-020-01401-2. Virol J. 2020. PMID: 32907596 Free PMC article.
-
Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.Int J Biol Sci. 2020 Mar 15;16(10):1724-1731. doi: 10.7150/ijbs.45498. eCollection 2020. Int J Biol Sci. 2020. PMID: 32226290 Free PMC article. Review.
-
Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis.Am J Physiol Cell Physiol. 2020 Aug 1;319(2):C258-C267. doi: 10.1152/ajpcell.00224.2020. Epub 2020 Jun 8. Am J Physiol Cell Physiol. 2020. PMID: 32510973 Free PMC article.
-
Severe acute respiratory syndrome coronaviruses contributing to mitochondrial dysfunction: Implications for post-COVID complications.Mitochondrion. 2023 Mar;69:43-56. doi: 10.1016/j.mito.2023.01.005. Epub 2023 Jan 20. Mitochondrion. 2023. PMID: 36690315 Free PMC article. Review.
Cited by
-
Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy.Expert Opin Ther Targets. 2021 Jun;25(6):435-449. doi: 10.1080/14728222.2021.1952987. Epub 2021 Jul 15. Expert Opin Ther Targets. 2021. PMID: 34236922 Free PMC article. Review.
-
Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19.Clin Immunol. 2022 Nov;244:109093. doi: 10.1016/j.clim.2022.109093. Epub 2022 Aug 6. Clin Immunol. 2022. PMID: 35944881 Free PMC article. Review.
-
Mitochondrial quality control in human health and disease.Mil Med Res. 2024 May 29;11(1):32. doi: 10.1186/s40779-024-00536-5. Mil Med Res. 2024. PMID: 38812059 Free PMC article. Review.
-
A mid‑pandemic night's dream: Melatonin, from harbinger of anti‑inflammation to mitochondrial savior in acute and long COVID‑19 (Review).Int J Mol Med. 2024 Mar;53(3):28. doi: 10.3892/ijmm.2024.5352. Epub 2024 Feb 1. Int J Mol Med. 2024. PMID: 38299237 Free PMC article. Review.
-
Melatonin: Regulation of Viral Phase Separation and Epitranscriptomics in Post-Acute Sequelae of COVID-19.Int J Mol Sci. 2022 Jul 23;23(15):8122. doi: 10.3390/ijms23158122. Int J Mol Sci. 2022. PMID: 35897696 Free PMC article. Review.
References
-
- Acuna-Castroviejo D., Escames G., Rodriguez M.I., Lopez L.C. Melatonin role in the mitochondrial function. Frontiers in Bioscience. 2007;12:947–963. - PubMed
-
- Ahluwalia A., Brzozowska I.M., Hoa N., Jones M.K., Tarnawski A.S. Melatonin signaling in mitochondria extends beyond neurons and neuroprotection: Implications for angiogenesis and cardio/gastroprotection. Proceedings of the National Academy of Sciences of the United States of America. 2018;115:E1942–E1943. - PMC - PubMed
-
- Ahmed E.A. Recommendations for oncological surgical practice in COVID-19 pandemics: A review of literature. Sohag Medical Journal. 2020;24:63–68.
-
- Andersen L.P.H., Gögenur I., Rosenberg J., Reiter R.J. Pharmacokinetics of melatonin: The missing link in clinical efficacy? Clinical Pharmacokinetics. 2016;55:1027–1030. - PubMed
-
- Andersen L.P.H., Gögenur I., Rosenberg J., Reiter R.J. The safety of melatonin in humans. Clinical Drug Investigation. 2016;36:169–175. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous